Immatics Announces Full Year 2022 Financial Results and Corporate Update
21 mars 2023 07h31 HE
|
https://immatics.com/
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and...
BioNTech kündigt Übernahme von InstaDeep an, um Vorreiterrolle auf dem Gebiet KI-basierter Arzneimittelforschung, -design und -entwicklung zu stärken
10 janv. 2023 07h15 HE
|
BioNTech SE
Geplante Übernahme ermöglicht den Aufbau vollständig integrierter, unternehmensweiter Kapazitäten zur Erforschung, Konzeption und Entwicklung von Immuntherapien der nächsten Generation im großen...
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
10 janv. 2023 07h15 HE
|
BioNTech SE
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging artificial intelligence and...
Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
17 nov. 2022 07h00 HE
|
Immatics N.V.
Klinisches Daten-Update zu ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigt hohe bestätigte objektive Ansprechrate (confirmed objective response rate, cORR) von 50 % (6/12) bei...
Immatics Announces Third Quarter 2022 Financial Results and Business Update
17 nov. 2022 07h00 HE
|
https://immatics.com/
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and...
EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10 nov. 2022 09h00 HE
|
EvolveImmune
Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of...
EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy
24 oct. 2022 07h00 HE
|
EvolveImmune
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Presentation Highlights CD2 as an Optimal Costimulatory...
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
20 oct. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences
18 oct. 2022 07h00 HE
|
EvolveImmune
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Poster Presentations Scheduled for American Association...
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
17 oct. 2022 14h27 HE
|
NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...